Kirby Institute
- Country
- π¦πΊAustralia
- Ownership
- Private
- Established
- 1986-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://kirby.unsw.edu.au
The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 313
- Registration Number
- NCT04132479
- Locations
- π²π²
Insein General Hospital, Yangon, Myanmar
Simplified Monitoring Myanmar SM2 Study
- Conditions
- Liver InflammationHepatitis CHIV InfectionsLiver Cirrhoses
- Interventions
- Device: HCV point of care machine
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 200
- Registration Number
- NCT04113629
- Locations
- π¦πΊ
The Kirby Institute, University of New South Wales Australia, Sydney, New South Wales, Australia
Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Diagnostic Test: Xpert HCV Viral Load FingerstickDiagnostic Test: Aptima HCV Quant DX Assay
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 2700
- Registration Number
- NCT04014179
- Locations
- π¦πΊ
Coffs Harbour Primary NSP, Coffs Harbour, New South Wales, Australia
π¦πΊLiverpool Southwest NSP, Liverpool, New South Wales, Australia
π¦πΊUC Adelaide, Adelaide, South Australia, Australia
Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs
- Conditions
- Hepatitis CLiver CirrhosesLiver Inflammation
- Interventions
- Drug: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral TabletDrug: Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03981211
- Locations
- π¦πΊ
Royal Adelaide Hospital, Adelaide, South Australia, Australia
π¦πΊThe Alfred Hospital, Melbourne, Victoria, Australia
π¦πΊSt Vincent's Hospital, Melbourne, Victoria, Australia
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
- Conditions
- Hepatitis C
- Interventions
- Drug: Sofosbuvir 400mg [Sovaldi]Drug: Glecaprevir/pibrentasvir (300mg/120mg)
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03855917
- Locations
- π¦πΊ
Blacktown Mt Druitt Hospital, Sydney, New South Wales, Australia
π¦πΊRoyal Adelaide Hospital, Adelaide, South Australia, Australia
π¦πΊSt Vincent's Hospital, Darlinghurst, New South Wales, Australia
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
- Conditions
- Hepatitis CHepatitisLiver DiseasesHepatitis, Viral, HumanRNA Virus InfectionsDigestive System Diseases
- Interventions
- Drug: glecaprevir/pibrentasvirDevice: Fingerstick GeneXpert HCV RNA quantitative assayDrug: sofosbuvir/velpatesvir
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 600
- Registration Number
- NCT03776760
- Locations
- π¦πΊ
Jullums Lismore Aboriginal Medical Service, Lismore, New South Wales, Australia
π¦πΊWalhallow Aboriginal Corporation, Quirindi, New South Wales, Australia
π¦πΊPangula Mannamurna Aboriginal Corporation, Mount Gambier, South Australia, Australia
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 202
- Registration Number
- NCT03740906
- Locations
- π¦πΊ
NSW Correctional Centres, Sydney, New South Wales, Australia
Impact of the Daily Doxycycline Pre-exposure Prophylaxis (PrEP) on the Incidence of Syphilis, Gonorrhoea and Chlamydia
- Conditions
- STIs Prevention
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03709459
- Locations
- π¦πΊ
Royal Prince Alfred Hospital Sexual Health Medicine, Camperdown, New South Wales, Australia
π¦πΊKirketon Road Centre, Sydney, New South Wales, Australia
π¦πΊMelbourne Sexual Health Centre, Melbourne, Victoria, Australia
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
- Conditions
- Hepatitis C
- Interventions
- Procedure: Campaign days
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 6000
- Registration Number
- NCT03685045
- Locations
- π¦πΊ
Lawrence Avenue Methadone Program (LAMP), Nowra, New South Wales, Australia
π¦πΊWSLHD Mount Druitt Drug Health OST Clinic, Mount Druitt, New South Wales, Australia
π¦πΊNSLHD Brookvale Community Health Centre, Brookvale, New South Wales, Australia
Body Composition Sub-study of the D2EFT Trial
- Conditions
- HIV Infections
- Interventions
- Drug: Darunavir (DRV) 800 milligram (MG) Oral TabletDrug: TDF 300 MG Oral TabletDrug: Ritonavir 100 MG Oral TabletDrug: N(t)RTIsDrug: 3TC 300 MG Oral TabletDrug: Dolutegravir 50 MG Oral TabletDrug: FTC 200 MG Oral Cap
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 155
- Registration Number
- NCT03675815
- Locations
- πΏπ¦
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, Johannesburg, South Africa
πΏπ¦Clinical HIV Research Unit, Helen Joseph Hospital, Westdene, Johannesburg, South Africa
πΏπ¦Desmond Tutu HIV Foundation, Cape Town, South Africa